Molecular characteristics of gastric cancer with ERBB2 amplification
Gastric cancer is a prevalent malignancy with a high degree of heterogeneity, which has led to a poor therapeutic response. Though there are numerous HER2-targeted medicines for HER2+ gastric cancer, many trials have not indicated an improvement in overall survival. Here 29 ERBB2 amplification (ERBB...
Main Authors: | Dongyan Cao, Hongping Xu, Longteng Li, Zheng Ju, Baiqiang Zhai |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-08-01
|
Series: | Heliyon |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023058620 |
Similar Items
-
Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01) -
Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies
by: Nannan Wang, et al.
Published: (2022-10-01) -
Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
by: Javier Torres-Jiménez, et al.
Published: (2022-07-01) -
Upregulated Expression of ERBB2/HER2 in Multiple Myeloma as a Predictor of Poor Survival Outcomes
by: Fatih M. Uckun, et al.
Published: (2023-06-01) -
Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors
by: Yin Guan, et al.
Published: (2022-10-01)